Patient characteristics
. | All patients . | Patients with early interim PET . | Patients with no early interim PET . |
|---|---|---|---|
| No. | 99 | 77 | 22 |
| Age, y | |||
| Mean | 40.5 | 40.1 | 42.0 |
| Median | 36.2 | 36.2 | 39.4 |
| Range | 18.6-79.2 | 18.6-74.0 | 19.0-79.2 |
| Follow-up, mo | |||
| Mean | 22,7 | 23.4 | 20.1 |
| Median | 20.8 | 22.8 | 18.7 |
| Range | 2.0-40.8 | 6.1-40.8 | 2.0-38.5 |
| 2-year PFS, % | 80.2 | 80.7 | 78.3 |
| Sex (%) | |||
| Male | 61 (62) | 49 (64) | 12 (55) |
| Female | 38 (38) | 28 (36) | 10 (46) |
| Clinical stage (%) | |||
| I | 22 (22) | 15 (20) | 7 (32) |
| II | 42 (42) | 33 (43) | 9 (41) |
| III | 27 (27) | 23 (30) | 4 (18) |
| IV | 8 (8) | 6 (8) | 2 (9) |
| No. of regions | |||
| Mean | 3.10 | 3.22 | 2.68 |
| Median | 3 | 3 | 2.5 |
| Range | 1-10 | 1-10 | 1-6 |
| Extranodal disease (%) | |||
| Yes | 18 (18) | 14 (18) | 4 (18) |
| No | 81 (82) | 63 (82) | 18 (82) |
| B symptoms (%) | |||
| Yes | 52 (53) | 40 (52) | 12 (55) |
| No | 47 (48) | 37 (48) | 10 (46) |
| Bulky disease (%) | |||
| Yes | 31 (31) | 26 (34) | 5 (23) |
| No | 68 (69) | 51 (66) | 17 (77) |
| Histologic type (%) | |||
| NS | 61 (62) | 51 (66) | 10 (46) |
| MC | 20 (20) | 17 (22) | 3 (14) |
| CHL, NOS | 8 (8) | 3 (4) | 5 (23) |
| NLP | 10 (10) | 6 (8) | 4 (18) |
| IPS, 1-7 | |||
| Mean | 2.77 | 2.82 | 2.59 |
| Median | 3 | 3 | 2.5 |
| Range | 1-6 | 1-5 | 1-6 |
| First-line treatment (%) | |||
| ABVD | 85 (86) | 70 (91) | 15 (68) |
| ABV/MOPP | 3 (3) | 2 (3) | 1 (5) |
| ABVD/COPP | 2 (2) | 2 (3) | 0 (0) |
| BEACOPP esc. | 2 (2) | 2 (3) | 0 (0) |
| PVAG | 2 (2) | 1 (1) | 1 (5) |
| Radiotherapy only | 5 (5) | 0 (0) | 5 (23) |
| Clinical outcome (%) | |||
| Progression | 18 (18) | 14 (18) | 4 (18) |
| Death | 5 (5) | 2 (3) | 3 (14) |
. | All patients . | Patients with early interim PET . | Patients with no early interim PET . |
|---|---|---|---|
| No. | 99 | 77 | 22 |
| Age, y | |||
| Mean | 40.5 | 40.1 | 42.0 |
| Median | 36.2 | 36.2 | 39.4 |
| Range | 18.6-79.2 | 18.6-74.0 | 19.0-79.2 |
| Follow-up, mo | |||
| Mean | 22,7 | 23.4 | 20.1 |
| Median | 20.8 | 22.8 | 18.7 |
| Range | 2.0-40.8 | 6.1-40.8 | 2.0-38.5 |
| 2-year PFS, % | 80.2 | 80.7 | 78.3 |
| Sex (%) | |||
| Male | 61 (62) | 49 (64) | 12 (55) |
| Female | 38 (38) | 28 (36) | 10 (46) |
| Clinical stage (%) | |||
| I | 22 (22) | 15 (20) | 7 (32) |
| II | 42 (42) | 33 (43) | 9 (41) |
| III | 27 (27) | 23 (30) | 4 (18) |
| IV | 8 (8) | 6 (8) | 2 (9) |
| No. of regions | |||
| Mean | 3.10 | 3.22 | 2.68 |
| Median | 3 | 3 | 2.5 |
| Range | 1-10 | 1-10 | 1-6 |
| Extranodal disease (%) | |||
| Yes | 18 (18) | 14 (18) | 4 (18) |
| No | 81 (82) | 63 (82) | 18 (82) |
| B symptoms (%) | |||
| Yes | 52 (53) | 40 (52) | 12 (55) |
| No | 47 (48) | 37 (48) | 10 (46) |
| Bulky disease (%) | |||
| Yes | 31 (31) | 26 (34) | 5 (23) |
| No | 68 (69) | 51 (66) | 17 (77) |
| Histologic type (%) | |||
| NS | 61 (62) | 51 (66) | 10 (46) |
| MC | 20 (20) | 17 (22) | 3 (14) |
| CHL, NOS | 8 (8) | 3 (4) | 5 (23) |
| NLP | 10 (10) | 6 (8) | 4 (18) |
| IPS, 1-7 | |||
| Mean | 2.77 | 2.82 | 2.59 |
| Median | 3 | 3 | 2.5 |
| Range | 1-6 | 1-5 | 1-6 |
| First-line treatment (%) | |||
| ABVD | 85 (86) | 70 (91) | 15 (68) |
| ABV/MOPP | 3 (3) | 2 (3) | 1 (5) |
| ABVD/COPP | 2 (2) | 2 (3) | 0 (0) |
| BEACOPP esc. | 2 (2) | 2 (3) | 0 (0) |
| PVAG | 2 (2) | 1 (1) | 1 (5) |
| Radiotherapy only | 5 (5) | 0 (0) | 5 (23) |
| Clinical outcome (%) | |||
| Progression | 18 (18) | 14 (18) | 4 (18) |
| Death | 5 (5) | 2 (3) | 3 (14) |
PFS indicates progression-free survival; NS, nodular sclerosis; MC, mixed cellularity; CHL, classic Hodgkin lymphoma; NOS, not otherwise specified; NLP, nodular lymphocyte predominance; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ABV/MOPP, adriamycin, bleomycin, vinblastine, mechlorethamine, vincristine, procarbazine, prednisone; ABVD/COPP, cyclophosphamide, vincristine, procarbazine, prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; and PVAG, prednisone, vinblastine, doxorubicin, gemcitabine.